ABSTRACT
OBJECTIVE: To determine the usefulness of medical infrared thermal imaging (MITI) as a screening tool for hyperthyroidism in cats, evaluate the need for hair clipping over the ventral aspect of the neck to achieve optimal images, and determine whether there is a change in thermal patterns at 1 and 3 months after radioactive sodium iodide I 131 treatment. ANIMALS: 17 cats with and 12 control cats without hyperthyroidism. PROCEDURES: All cats underwent MITI first with the hair present and then after the hair was clipped. Each cat with hyperthyroidism was subsequently appropriately treated SC with radioiodide; reevaluations, including MITI before and after hair clipping and measurement of serum thyroxine concentration, were performed 1 and 3 months after treatment. RESULTS: The MITI had 80.5% and 87.5% accuracy in differentiating hyperthyroid cats from clinically normal cats before and after the hair over the ventral aspect of the neck was clipped. Among cats with an initial serum thyroxine concentration > 4.0 µg/dL, the success rate for MITI-detected response to radioiodide treatment at the 1-month reevaluation was 92.86% in unshaved cats and 85.71% in shaved cats. The success rate for MITI-detected response to radioiodide treatment at the 3-month reevaluation was 100% in unshaved and shaved cats. CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that MITI was successful in differentiating between hyperthyroid cats and clinically normal cats and identifying patients with thyroxine concentration within reference interval after radioactive sodium iodide I 131 treatment.
Subject(s)
Cat Diseases/diagnosis , Hyperthyroidism/veterinary , Infrared Rays , Animals , Cat Diseases/blood , Cat Diseases/radiotherapy , Cats , Female , Hyperthyroidism/diagnosis , Image Interpretation, Computer-Assisted , Iodine Radioisotopes/therapeutic use , Male , Preoperative Care/veterinary , Thyroxine/bloodSubject(s)
Carcinoma/veterinary , Cat Diseases/diagnostic imaging , Lung Neoplasms/veterinary , Animals , Barium Sulfate , Carcinoma/diagnostic imaging , Carcinoma/pathology , Cats , Fatal Outcome , Female , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Neoplasm Metastasis , Radiography, Thoracic/veterinaryABSTRACT
Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m(2), was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.
